We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
P2Y<sub>12</sub> Receptor Inhibitors in Acute Coronary Syndromes: From the Research Laboratory to the Clinic and Vice Versa.
- Authors
Alexopoulos, Dimitrios
- Abstract
The P2Y12 receptor plays a pivotal role in platelet activation and aggregation through a complex cascade of actions. Laboratory and clinical data have convincingly shown the benefit of P2Y12 inhibition combined with aspirin in patients with acute coronary syndrome (ACS)/undergoing percutaneous coronary intervention (PCI). Newer agents - like prasugrel, ticagrelor, and cangrelor - provide more consistent, faster, and stronger platelet inhibition than clopidogrel. In large clinical trials newer agents have resulted in fewer ischemic complications (though with increased bleeding potential) than clopidogrel. High-risk subpopulations like ST-segment elevation myocardial infarction, diabetes, chronic kidney disease, elderly, and low body weight patients have been identified. A 'return to the laboratory' has been observed recently, with several pharmacodynamic studies being performed particularly in these cohorts. This interplay between research laboratory and clinical data may lead to a more efficient and safer use of P2Y12 inhibitors. © 2014 S. Karger AG, Basel
- Subjects
ACUTE coronary syndrome; ASPIRIN; PURINERGIC receptors; PLATELET aggregation inhibitors; CARDIOLOGY
- Publication
Cardiology, 2014, Vol 127, Issue 4, p211
- ISSN
0008-6312
- Publication type
Article
- DOI
10.1159/000357399